Burger DM - Search Results

1

Rethinking the risk-benefit ratio of efavirenz in HIV-infected children.

Van de Wijer L, Schellekens AFA, Burger DM, Homberg JR, de Mast Q, van der Ven AJAM. Van de Wijer L, et al. Among authors: burger dm. Lancet Infect Dis. 2016 May;16(5):e76-e81. doi: 10.1016/S1473-3099(16)00117-1. Epub 2016 Apr 18. Lancet Infect Dis. 2016. PMID: 27599655 Review.

2

Pros and cons of therapeutic drug monitoring of antiretroviral agents.

Burger DM, Aarnoutse RE, Hugen PW. Burger DM, et al. Curr Opin Infect Dis. 2002 Feb;15(1):17-22. doi: 10.1097/00001432-200202000-00004. Curr Opin Infect Dis. 2002. PMID: 11964901

3

Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients.

Aarnoutse RE, Brinkman K, Benetucci J, Begovac J, Stek M Jr, Burger DM. Aarnoutse RE, et al. Among authors: burger dm. AIDS. 2004 Feb 20;18(3):565-7. doi: 10.1097/00002030-200402200-00026. AIDS. 2004. PMID: 15090812

4

Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.

Fraaij PL, Neubert J, Bergshoeff AS, van Rossum AM, Hartwig NG, Schroten H, Korn K, Burger DM, de Groot R, Niehues T. Fraaij PL, et al. Among authors: burger dm. Antivir Ther. 2004 Apr;9(2):297-9. Antivir Ther. 2004. PMID: 15134193 Clinical Trial.

5

Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.

Bergshoeff AS, Fraaij PL, Verweij C, van Rossum AM, Verweel G, Hartwig NG, de Groot R, Burger DM. Bergshoeff AS, et al. Among authors: burger dm. J Antimicrob Chemother. 2004 Dec;54(6):1152-4. doi: 10.1093/jac/dkh490. Epub 2004 Nov 10. J Antimicrob Chemother. 2004. PMID: 15537694 Clinical Trial.

6

Highly active antiretroviral therapy for HIV infection: lessons for the future.

Burger DM, van der Ven AJ, Koopmans PP. Burger DM, et al. Neth J Med. 2004 Dec;62(11):407-8. Neth J Med. 2004. PMID: 15685891 Free article.

7

Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

Bergshoeff AS, Fraaij PL, Ndagijimana J, Verweel G, Hartwig NG, Niehues T, De Groot R, Burger DM. Bergshoeff AS, et al. Among authors: burger dm. J Acquir Immune Defic Syndr. 2005 May 1;39(1):63-8. doi: 10.1097/01.qai.0000155203.89350.85. J Acquir Immune Defic Syndr. 2005. PMID: 15851915 Clinical Trial.

8

Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.

Droste JA, Kearney BP, Hekster YA, Burger DM. Droste JA, et al. Among authors: burger dm. J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):37-43. doi: 10.1097/01.qai.0000191997.70034.80. J Acquir Immune Defic Syndr. 2006. PMID: 16340471

9

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.

Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C, Koopmans P, Kroon F, Sprenger H, Lindemans J, Schenk P, van Schaik R. Burger D, et al. Br J Clin Pharmacol. 2006 Feb;61(2):148-54. doi: 10.1111/j.1365-2125.2005.02536.x. Br J Clin Pharmacol. 2006. PMID: 16433869 Free PMC article.

10

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

van der Lee M, Verweel G, de Groot R, Burger D. van der Lee M, et al. Antivir Ther. 2006;11(4):439-45. Antivir Ther. 2006. PMID: 16856617 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

554 results

Search Page